|
| 血液游离DNA在卵巢癌中的研究进展 |
| Advances in Research on cell-free DNA in ovarian cancer |
| 投稿时间：2024-07-07 修订日期：2024-10-04 |
| DOI： |
|
 |
| 中文关键词: 卵巢癌 cfDNA ctDNA |
| 英文关键词:Ovarian cancer cfDNA ctDNA |
| 基金项目:国家自然科学基金资助项目（项目编号:82172993）；陕西省卫生健康妇科肿瘤疾病科研创新平台（项目编号:2023PT-07）；陕西省重点研发计划项目（项目编号:2024SF-ZDCYL-01-17） |
|
| 摘要点击次数: 121 |
| 全文下载次数: 2 |
| 中文摘要: |
| 卵巢癌是最致命的妇科恶性肿瘤之一。尽管精准医学的发展改善了卵巢癌患者的生存状况，但五年生存率仍低于50%。液体活检是利用人体体液作为标本检测疾病的技术，通过分析释放到外周循环中的血液游离DNA（cell-free DNA, cfDNA）等肿瘤成分，可结合高通量测序技术，纵向监测肿瘤动态变化。它具有非侵入性、较高可及性等优势。越来越多的证据表明，利用液体活检技术协助早期诊断、预测预后以及监测治疗反应和复发，从而指导肿瘤的临床治疗决策，在临床中具有重要价值。因此，本文旨在将cfDNA在卵巢癌临床诊疗中的进展进行综述，以期为cfDNA在卵巢癌中的应用价值提供一定依据。 |
| 英文摘要: |
| Ovarian cancer is among the most lethal gynecological malignancies. Although precision medicine has improved survival for ovarian cancer patients, the five-year survival rate remains below 50%. Liquid biopsy is a technology that utilizes human body fluids as specimens to detect diseases. By analyzing tumor components like cell-free DNA (cfDNA) in the peripheral circulation, liquid biopsy can be combined with high-throughput sequencing to monitor tumor dynamics over time. This technique offers the advantages of being non-invasive and highly accessible. Increasing evidence shows that liquid biopsy technology holds great clinical value in assisting early diagnosis, prognosis prediction, and monitoring treatment response and recurrence, guiding clinical treatment decisions. This article aims to review the progress of cfDNA in the diagnosis and treatment of ovarian cancer to provide a basis for its application in this disease. |
|
在线阅读
查看全文 查看/发表评论 下载PDF阅读器 |